Methylphenidate vs amphetamine: what research shows in adults

Almost every stimulant prescribed for ADHD belongs to one of two families. The amphetamine family includes Adderall, Adderall XR, Vyvanse, Mydayis and dextroamphetamine products. The methylphenidate family includes Ritalin, Concerta, Focalin, Azstarys and others. This page looks at what head-to-head research and network meta-analyses say about the two families in adults, as of October 2026, and at the label differences that matter in daily life.

The families side by side

What the largest analysis found in adults

The most cited comparison is a 2018 network meta-analysis in the Lancet Psychiatry by Cortese and colleagues. It pooled 133 double-blind randomized trials, 51 of them in adults, with an efficacy analysis that included 8,131 adults. "Amphetamines" included lisdexamfetamine, and "methylphenidate" included dexmethylphenidate. Results at about 12 weeks, in adults:

• Against placebo (clinician ratings): amphetamines had a standardized mean difference of about 0.79 and methylphenidate about 0.49. Both clearly beat placebo.
• Head to head: the only differences found were in efficacy, favoring amphetamines over methylphenidate (and over atomoxetine and modafinil) in adults.
• Tolerability: both families were less well tolerated than placebo in adults, measured by dropouts because of side effects. The odds ratio was about 3.3 for amphetamines and 2.4 for methylphenidate, with wide confidence intervals.
• Conclusion: the authors wrote that the evidence "supports methylphenidate in children and adolescents, and amphetamines in adults, as preferred first-choice medications for the short-term treatment of ADHD."

Important limits come with that. Confidence in many comparisons was rated low or very low, especially indirect ones. There was not enough data at 26 or 52 weeks to compare the medicines over longer periods. And a group average does not say how any one adult will respond.

What newer evidence and guidelines add

• Ostinelli 2025, Lancet Psychiatry. This adult-only analysis of 113 trials treated "stimulants" as one component and found them effective on both self-reported and clinician-reported scales, with acceptability similar to placebo. It did not split amphetamines from methylphenidate in its headline results, and it found no medication benefit on quality of life.
• NICE (UK). Recommends lisdexamfetamine or methylphenidate as first-line for adults. It suggests switching to lisdexamfetamine after a six-week methylphenidate trial without enough benefit, and to methylphenidate after a six-week lisdexamfetamine trial without enough benefit.
• American Family Physician (2024). Describes a subset of amphetamine and methylphenidate stimulants as first-line for adults, without ranking the families.

The switching advice in NICE reflects a practical reality: an adult who does not do well on one family may do well on the other. That is why the family question is often settled by trying, with a prescriber, rather than by a rule. How doctors choose an ADHD medication covers the other factors involved.

Choices within each family

Choosing a family is only half the decision, because each family has short-acting and long-acting products built in different ways. On the amphetamine side, Adderall IR tablets are short-acting, Adderall XR capsules hold immediate- and delayed-release beads that can be sprinkled on applesauce, and Vyvanse is a prodrug that comes as capsules (which can be mixed into yogurt, water or orange juice) or chewable tablets. On the methylphenidate side, Ritalin tablets are short-acting, Concerta is an extended-release tablet that must be swallowed whole, and Focalin XR capsules hold beads that can be sprinkled on applesauce. These details often matter as much as the family itself for someone who cannot swallow tablets or needs coverage late into the day. Extended-release ADHD medications explained describes each release system.

Label differences that matter in practice

• Eyes. Methylphenidate labels list acute angle-closure glaucoma and increased intraocular pressure. Someone with glaucoma should raise this before starting.
• Priapism. Methylphenidate labels list priapism (a prolonged, painful erection) as a warning that needs prompt medical attention.
• Stomach acid and urine pH. Amphetamine labels warn that alkalinizing agents such as sodium bicarbonate raise levels and acidifying agents such as ascorbic acid lower them. The Adderall XR label also lists proton pump inhibitors.
• Other approvals. Vyvanse is also approved for binge eating disorder in adults; Adderall IR and Ritalin are also approved for narcolepsy.
• Age wording. Some methylphenidate labels stop at 65 (Concerta). Some products in both families are labeled only for children, which ADHD medications approved for adults in 2026 lists.

Shared warnings include serious heart disease, blood pressure and heart rate increases, new psychotic or manic symptoms, circulation problems in fingers and toes, serotonin syndrome with some drugs, tics, and the MAOI contraindication.

New York and New Jersey rules apply equally

Both families are Schedule II, so changing families does not change the prescription rules. New York does not allow Schedule II refills (10 NYCRR 80.67), and neither do New Jersey's controlled dangerous substance rules (N.J.A.C. 13:45H-7.9). See New York's rules for ADHD stimulant prescriptions and New Jersey's rules. Supply can differ: as of October 19, 2026, the FDA lists shortages in both families, detailed in the table above. See what to do when your pharmacy is out of stock.

Questions worth asking

• Have I tried either family before, as a child or adult, and what happened?
• Do I have glaucoma, heart disease, high blood pressure or a seizure history?
• Which of my other medicines interact with either family?
• If the first family does not help enough, how long before we try the other?

Talking it through with a prescriber

Dr. Shershow is a psychiatrist who focuses on adult ADHD and is licensed in New York and New Jersey. After an adult ADHD evaluation, he discusses the treatment options that fit, including medication when it is appropriate, and follows up over time. The comparison above is general information from FDA labels and published research. It is not advice to start, stop or switch any medication, and neither family is the right choice for everyone.